Silence Therapeutics (SLN) stock was initiated by Goldman Sachs with a Sell recommendation citing potential funding challenges for the company. Read more here.

In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against other most promising gene editing stocks to buy according to hedge funds.

Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.

To get a sense of who is truly in control of Silence Therapeutics plc (NASDAQ:SLN), it is important to understand the ownership structure of the business. And the group that holds the biggest ...

French mining group Eramet said on Wednesday it had reached an agreement with the French government to continue its subsidiary SLN’s mining operations in New Caledonia’s Northern Province.

Silence Therapeutics plc (NASDAQ:SLN) is a biotechnology company focused on developing innovative RNA-based therapeutics for hematology, cardiovascular diseases, and other rare and metabolic ...